BUZZ — New mid — term targets lift Lonza shares
* Swiss contract drug manufacturer Lonza rises 2.2% after setting new mid-term targets and confirming its 2026 outlook * Lonza targets 10% to 13% organic sales growth and a core EBITDA margin in the high thirties in the medium term * Vontobel says the updated targets imply some upside to its estimates and sees free cas